Sionna Stock 144% This Year: Is the Biotech a Buy Now?
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Introductory guidance on choosing long-term holds for beginners, focusing on fundamentals, liquidity, and project viability.
27,784 articlesSionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
A retired couple with a $2 million dividend portfolio faced a $14,400 cut in annual income but chose not to sell. The...
A Jordan base attack left two U.S. service members dead and one missing as tensions flare with Iran. The fallout hits...
A deep dive into MiB: Bill Gurley, Benchmark—how a pioneering VC built a team culture, backed Uber and other giants, ...
Lucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
A new security study shows post-hack damage outpaces the initial theft. In 2026, projects confront funding cuts, dela...
When a global star resurfaces at a major awards show, money, trust, and hype collide. This piece breaks down the cont...
Oklo faced a sharp pullback in early 2026 as sector bets cooled and financing moves pressured shares. This guide brea...
Two specialty retailers sit on opposite ends of the consumer tech spectrum. By unpacking their revenue trends, invest...
Retirement is more than budgeting for groceries and utilities. This guide reveals three hidden costs retirees often m...
A new leadership ethos is taking hold among billionaire founders and operators. As markets shift in early 2026, many ...
Retired couples can unlock cash from big gains without federal taxes by coordinating income and investments within th...